HELSINKI, May 4, 2022 /PRNewswire/ — Nanoform Finland Plc., an innovative nanoparticle-based medicine aid company, today announced the launch of its rare data AI solution (STARMAP® Online) as a secure online portal for the direct use of its current and future partners.
Since its creation in 2020, STARMAP® has been actively used by Nanoform to provide its customers with a reliable assessment of the suitability of their molecules for the controlled expansion of supercritical solutions (CESS®)1 nanoparticle engineering.
STARMAP® is a digital version of the CESS® technology that allows silicone experiments to determine which molecules should be nanoformed.
Nanoform’s legacy processes involved handling all analyzes in-house after receiving specific molecular attributes from its customers.
STARMAP® Online was launched at the direct request of current and future Nanoform partners looking to maintain the STARMAP level of trust® offers, while integrating it into their own internal molecule selection processes. STARMAP® Online creates the opportunity for customers to perform a large number of in silico CESS® experiments from their office, before approaching Nanoform for experimental validation. This approach further supports Nanoform’s green ambition by ensuring that Nanoform advances molecules with the greatest likelihood of success.
STARMAP® Online provides increased user confidence through:
- Safety and security – the interface was developed in accordance with ISO27001:2017 standards.
- Customer submissions are only seen by customers (not Nanoform), allowing molecules to be screened without sharing structures. The results are presented directly to the customer via the system.
- Scalability and agility: The ability to manage thousands of molecules in a single submission to support candidate selection from molecule libraries is possible.
- New information: STARMAP® Online contains a database of over 17,000 pre-reviewed and publicly disclosed drugs and candidates. Clients can request topical reviews and understand the power of CESS® in different therapeutic areas, target classes and disease areas.
“This May 4andSTARMAP® Online opens up new galaxies of potential and we are excited to increase access for the pharmaceutical community. Technology has significant potential impact, enabling viable CESSs® candidates to be identified quickly. STARMAP® Online has the potential to transform patients’ lives by accelerating the development of new therapies, supporting our mission to touch the lives of one billion patients with nanoformed medicines,” said Professor Edward Hæggström, CEO of Nanoform.
1 (CESS® is a nanoparticle platform technology that produces pure homogeneous drug particles from solution in an excipient-free process. By reducing the particle size, for example from 10 microns to 50 nm, the specific surface can be increased up to 1000 times, thus improving the dissolution rate, solubility and bioavailability. Therefore, Nanoform can help pharma partners advance the development of molecules that otherwise might not have been possible. It also opens up exciting possibilities for a wide range of new drug delivery applications.)
For more information, please contact:
[email protected] / +44 7804 474771
For investor relations matters, please contact:
Henry von HaartmanInvestor Relations Director
[email protected] / +46 7686 650 11
Nanoform is an innovative company promoting nanoparticle medicine. Nanoform works with pharmaceutical and biotechnology partners around the world to bring hope to patients in the development of new and improved medicines using Nanoform’s platform technologies. The Company is focused on reducing clinical attrition and improving drug molecule performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small and large molecule development space with a focus on addressing key drug solubility and bioavailability issues and enabling new drug applications. administration of drugs. Nanoform shares are listed on the Premier Segment of the Nasdaq First North Growth Market in helsinki (symbol: NANOFH) and stockholm (symbol: NANOFS). Certified Advisor: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit http://www.nanoform.com
This company release contains forward-looking statements, including, but not limited to, statements regarding Nanoform’s strategy, business plans and direction. The words may, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements contained in this company release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and factors that may cause actual events or results to differ. actual results differ materially from those expressed or implied by any forward-looking statements. statements contained in this company release, including, but not limited to, those related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and expected timelines and competition from other companies. Nanoform cautions you not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which such statements may be based, or which may affect the likelihood that actual results will differ from those set forth in forward-looking statements. All forward-looking statements contained in this company release represent the views of Nanoform only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: